IP Library Granted Patent US 9,089,594
Granted Patent B2
US 9,089,594 · App. 12/830,652 · Granted Jul 28, 2015

Methods and compositions for tissue augmentation

Inventors: Wallace K. Dyer (Atlanta, GA); Inna Dyer (Atlanta, GA)
Assignee: Wallace K. Dyer
A61K31/74A61K9/0019A61L27/14A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,089,594
App. No.
12/830,652
Granted
Jul 28, 2015
Kind
B2
Abstract

Methods and compositions for use in tissue volume replacement are provided. The present invention comprises compositions comprising a combination of materials, comprising preferably a solid polymer particle phase and a gel phase, and also comprises single phase compositions. More particularly, preferred embodiments comprise a solid polymer particle phase made of materials comprising Gore-Tex (micronized e-PTFE), PDS II (polydioxanone, a monofilament), NUROLON (a long chain aliphatic polymer Nylon 6 or Nylon 6,6) ETHILON (a long chain aliphatic polymer Nylon 6 and Nylon 6,6), PROLENE (Polypropylene, isotactic crystalline stereoisomer of polypropylene, a synthetic linear polyolefin.), VICRYL (copolymer made from 90% glycolide and 10% L-lactide), silk, MONACRYL (poly ε-caprolactone.), polylactide, polyglycolide, poly lactide-co-glycolide, and BIOPOL (polyhydroxyvalerate), MEDPOR (biocompatible (micronized) polyethylene), BIOGLASS (bioactive glass particulate), NOVABONE and NOVABONE-CM, and the gel phase comprises polyvinylpyrrolidone (PVP). Preferred single phase compositions comprise PVP. Methods of the present invention comprising injection of such compositions for tissue augmentation.

Claims (9)

1. A method for tissue augmentation comprising:

injecting a biphasic injectable composition comprising:

a solid polymer phase; and

a carrier substrate phase.

2. The method of claim 1 , wherein the solid polymer phase is made from micronized expanded polytetrafluoroethelene (“ePTFE”) particles, polydioxanone, long chain aliphatic polymers Nylon6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly E-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

3. The method of claim 1 , wherein the carrier substrate phase is selected from polyvinylpyrrolidone (“PVP”), silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, water or autologous plasma.

4. The method of claim 1 , wherein injecting comprises:

inserting a delivery apparatus containing the biphasic 20 injectable composition into the injection site.

5. The method of claim 1 , wherein the injecting comprises subcutaneous, intradermal, intramuscular, periurethral injection or injecting the vocal cords.

Continuity (2)
Continuation 11738132 · Apr 20, 2007
Related Publication 20110135705A1 · Jun 9, 2011